Medicamen Biotec

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE646B01010
  • NSEID: MEDICAMEQ
  • BSEID: 531146
INR
286.75
1.7 (0.6%)
BSENSE

Nov 20

BSE+NSE Vol: 5.37 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Albert David
Trident Lifeline
Medicamen Biotec
Aarey Drugs
Lyka Labs
Jenburkt Pharma
Ambalal Sarabhai
Astonea Labs
Ennature Bio Pha
Accretion Nutrav
Infinium Pharma
Why is Medicamen Biotech Ltd ?
1
Company has a low Debt to Equity ratio (avg) at 0.03 times
2
Poor long term growth as Operating profit has grown by an annual rate -2.86% of over the last 5 years
3
Positive results in Sep 26
  • NET SALES(9M) At Rs 163.38 cr has Grown at 36.35%
  • PAT(9M) At Rs 9.39 cr has Grown at 29.70%
  • PBDIT(Q) Highest at Rs 8.68 cr.
4
Stock is technically in a Mildly Bullish range
  • The technical trend has improved from Sideways on 06-Nov-26 and has generated 4.12% returns since then
  • The stocks Bollinger Band and KST technical factors are also Bullish
5
With ROE of 4.1, it has a Fair valuation with a 1.4 Price to Book Value
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of -29.16%, its profits have risen by 8.1% ; the PEG ratio of the company is 8.1
6
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -29.16% returns in the last 1 year, the stock has also underperformed BSE500 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Medicamen Biotec should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Medicamen Biotec for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Medicamen Biotec
-29.16%
-0.53
54.66%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
12.99%
EBIT Growth (5y)
-2.86%
EBIT to Interest (avg)
4.19
Debt to EBITDA (avg)
1.62
Net Debt to Equity (avg)
0.02
Sales to Capital Employed (avg)
0.66
Tax Ratio
18.98%
Dividend Payout Ratio
14.07%
Pledged Shares
0
Institutional Holding
4.40%
ROCE (avg)
6.39%
ROE (avg)
5.09%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
35
Industry P/E
40
Price to Book Value
1.43
EV to EBIT
26.22
EV to EBITDA
17.93
EV to Capital Employed
1.42
EV to Sales
1.95
PEG Ratio
8.14
Dividend Yield
0.34%
ROCE (Latest)
5.43%
ROE (Latest)
4.11%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company
NET SALES(9M)

At Rs 163.38 cr has Grown at 36.35%

PAT(9M)

At Rs 9.39 cr has Grown at 29.70%

PBDIT(Q)

Highest at Rs 8.68 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 15.83%

PBT LESS OI(Q)

Highest at Rs 5.12 cr.

-4What is not working for the Company
OPERATING CF(Y)

Lowest at Rs -33.17 Cr

Loading Valuation Snapshot...
Here's what is working for Medicamen Biotec
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 5.12 cr has Grown at 121.65%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Net Sales - Nine Monthly
At Rs 163.38 cr has Grown at 36.35%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Profit After Tax (PAT) - Nine Monthly
At Rs 9.39 cr has Grown at 29.70%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 8.68 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 15.83%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 5.12 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Here's what is not working for Medicamen Biotec
Operating Cash Flow - Annually
Lowest at Rs -33.17 Cr and Fallen
each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (Rs Cr)